Result of AGM

Report this content

27 April 2023 17:30 BST

Results of Annual General Meeting held on 27 April 2023

AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 9 - 13 were passed as special resolutions; all other resolutions were passed as ordinary resolutions.

Resolution Votes for % of votes cast Votes against % of votes cast Votes cast in total Total votes cast as a % of issued share capital Votes withheld
1 To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2022 1,264,644,490 99.80 2,524,193 0.20 1,267,168,683 81.76 2,068,894
2 To confirm dividends 1,254,919,878 98.92 13,679,112 1.08 1,268,598,990 81.85 638,576
3 To reappoint PricewaterhouseCoopers LLP as Auditor 1,260,792,714 99.39 7,718,080 0.61 1,268,510,794 81.85 726,500
4 To authorise the Directors to agree the remuneration of the Auditor 1,268,225,831 99.98 270,095 0.02 1,268,495,926 81.85 741,641
5a To re-elect Michel Demaré as a Director 1,241,496,328 97.88 26,829,809 2.12 1,268,326,137 81.84 911,430
5b To re-elect Pascal Soriot as a Director 1,260,336,535 99.37 7,986,485 0.63 1,268,323,020 81.83 914,729
5c To re-elect Aradhana Sarin as a Director 1,265,264,711 99.76 3,062,442 0.24 1,268,327,153 81.84 910,131
5d To re-elect Philip Broadley as a Director 1,259,273,602 99.29 9,043,851 0.71 1,268,317,453 81.83 920,114
5e To re-elect Euan Ashley as a Director 1,268,022,043 99.98 282,266 0.02 1,268,304,309 81.83 924,629
5f To re-elect Deborah DiSanzo as a Director 1,267,959,577 99.97 349,778 0.03 1,268,309,355 81.83 926,746
5g To re-elect Diana Layfield as a Director 1,268,027,536 99.98 274,653 0.02 1,268,302,189 81.83 935,378
5h To re-elect Sheri McCoy as a Director 1,241,492,257 97.88 26,842,094 2.12 1,268,334,351 81.84 903,216
5i To re-elect Tony Mok as a Director 1,261,574,735 99.97 322,367 0.03 1,261,897,102 81.42 7,338,922
5j To re-elect Nazneen Rahman as a Director 1,266,284,904 99.85 1,870,104 0.15 1,268,155,008 81.82 1,082,559
5k To re-elect Andreas Rummelt as a Director 1,268,030,928 99.98 285,793 0.02 1,268,316,721 81.83 920,846
5l To re-elect Marcus Wallenberg as a Director 1,026,140,887 80.93 241,825,345 19.07 1,267,966,232 81.81 1,263,367
6 To approve the Annual Report on Remuneration for the year ended 31 December 2022 1,195,261,107 94.23 73,125,360 5.77 1,268,386,467 81.84 850,827
7 To authorise limited political donations 1,228,047,446 97.76 28,189,687 2.24 1,256,237,133 81.06 13,000,783
8 To authorise the Directors to allot shares 1,166,174,071 91.95 102,088,563 8.05 1,268,262,634 81.83 966,964
9 To authorise the Directors to disapply pre-emption rights 1,193,686,193 94.15 74,121,064 5.85 1,267,807,257 81.80 1,430,310
10 To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments 1,153,850,923 91.25 110,689,108 8.75 1,264,540,031 81.59 4,697,303
11 To authorise the Company to purchase its own shares 1,254,158,039 98.92 13,730,760 1.08 1,267,888,799 81.81 1,348,767
12 To reduce the notice period for general meetings 1,178,311,157 93.41 83,098,807 6.59 1,261,409,964 81.39 7,827,602
13 To adopt new Articles of Association of the Company   1,258,637,857 99.26 9,327,063 0.74 1,267,964,920 81.81 1,272,646

A copy of the resolutions passed at the AGM (other than resolutions concerning ordinary business) has been submitted to the National Storage Mechanism for publication, and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

Issued capital

As at 25 April 2023, the number of issued shares of the Company was 1,549,856,584 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all of the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Adrian Kemp
Company Secretary

AstraZeneca PLC


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Subscribe

Documents & Links